Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Liquidia Corporation (NASDAQ: LQDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation focused on biopharmaceutical products for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD), Liquidia uses these filings to report financial results, material agreements, governance changes and other significant events.
Investors can review Forms 10‑K and 10‑Q for detailed discussions of Liquidia’s business, including its PRINT® technology platform, the commercialization of YUTREPIA™ (treprostinil) inhalation powder, development of the investigational L606 treprostinil liposome inhalation suspension, and promotion of generic Treprostinil Injection under a profit‑sharing agreement with Sandoz. These periodic reports typically include segment information, research and development spending, risk factors related to PAH and PH‑ILD markets, and descriptions of key contracts.
Current reports on Form 8‑K highlight specific events such as quarterly earnings releases, financing transactions under the revenue interest financing agreement with HealthCare Royalty Partners IV, L.P. (HCR), entry into the exclusive license with Vectura for the nebulizer device used with L606, leases for expanded manufacturing facilities in Morrisville, North Carolina, and outcomes of annual stockholder meetings. Other 8‑K filings may document executive appointments, compensation arrangements and other governance matters.
Users can also monitor proxy statements and Form 4 insider transaction reports to understand board elections, advisory votes on executive compensation and equity awards to officers and directors. Stock Titan’s interface combines these documents with AI‑powered summaries that explain complex sections of long filings, highlight key changes from prior periods and help clarify how new agreements, clinical developments or financing structures may affect Liquidia’s operations and capital structure.
With real‑time updates from EDGAR and structured access to historical filings, this page serves as a central resource for analyzing Liquidia’s regulatory history, capital markets activity and disclosures related to its treprostinil‑based therapies for PAH and PH‑ILD.
Schedule 13G filing: Farallon Capital Management and affiliated funds (collectively the “Reporting Persons”) disclosed passive ownership of Liquidia Corporation (ticker LQDA) common stock as of 07 July 2025.
Key holdings
- Largest direct holder: Farallon Partners, L.L.C. – 6,619,847 shares, representing 7.7 % of outstanding shares.
- Aggregate shares attributed to individual managing members (Joshua J. Dapice et al.) – 6,832,472 shares, or ≈8 % of the class.
- Significant underlying funds include:
- Farallon Healthcare Partners Master, L.P. – 2,601,710 shares (3 %).
- Farallon Capital Offshore Investors II, L.P. – 1,739,892 shares (2 %).
- Farallon Capital Institutional Partners, L.P. – 717,814 shares (0.8 %).
- Farallon Capital Partners, L.P. – 785,702 shares (0.9 %).
Each fund reports 0 shares with sole voting/dispositive power; all voting and dispositive power is shared among the Farallon entities. The filing is made on Schedule 13G, indicating a passive investment intent rather than an activist position (which would require a Schedule 13D).
The Reporting Persons certify that the securities were “not acquired and are not held for the purpose of or with the effect of changing or influencing control” of Liquidia. No other material transactions, agreements, or intentions were disclosed.
Liquidia Corporation (NASDAQ:LQDA) filed a Form 8-K to disclose the receipt of an additional USD 50 million under the Sixth Amendment to its Revenue Interest Financing Agreement with HealthCare Royalty Partners IV, L.P. (HCR).
The funds became available after two key milestones satisfied the agreement’s “Funding Condition”:
- May 30 2025: The U.S. District Court for the Middle District of North Carolina denied United Therapeutics Corporation’s request for a preliminary injunction and temporary restraining order against Liquidia.
- June 2 2025: Liquidia completed its first commercial shipment of YUTREPIA™ (treprostinil inhalation powder) for treatment of PAH and PH-ILD.
The company now has access to a cumulative USD 100 million under the HCR facility (USD 50 million drawn in March plus the new USD 50 million). A further USD 25 million tranche remains available if: (1) YUTREPIA net sales exceed USD 100 million by June 30 2026 and (2) both parties mutually agree to fund.
No earnings data were provided, and the filing contains no new financial statements. The disclosure highlights strengthened liquidity to support YUTREPIA’s commercial rollout while acknowledging ongoing—but presently unsuccessful—litigation efforts by a competitor.
Insider Trading Alert: Liquidia Corp (LQDA) Director Raman Singh received 18,396 Restricted Stock Units (RSUs) on June 17, 2025. The RSUs were granted at $0 cost and convert to common stock on a one-for-one basis.
Key Details:
- Following the transaction, Singh directly owns 38,755 shares
- The RSUs vest at the earlier of: one-year anniversary of grant date or day before next annual shareholder meeting
- Transaction was reported via Form 4 filing on June 28, 2025
- Filing location: 419 Davis Drive, Suite 100, Morrisville, NC
This equity grant appears to be part of standard director compensation arrangements. The transaction increases Singh's alignment with shareholder interests through expanded equity ownership in the company.
Director Katherine Rielly-Gauvin of Liquidia Corp (LQDA) reported the acquisition of 18,396 restricted stock units (RSUs) on June 17, 2025. The RSUs were granted at $0 cost and convert to common stock on a one-for-one basis.
Key details of the transaction:
- Following the transaction, Rielly-Gauvin directly owns 38,755 shares
- The RSUs vest at the earlier of: - One-year anniversary of grant date - Day before next annual shareholder meeting
- Transaction was reported within the required filing deadline
This equity grant appears to be part of the company's director compensation program, representing a standard annual stock award to align the director's interests with shareholders.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
